Navigation Links
ABSTRAL® (fentanyl) Sublingual Tablets CII, First-in-class, Sublingual, Immediate Release Opioid for Managing Breakthrough Cancer Pain, Now Available in the U.S.
Date:4/4/2011

l for misuse, abuse, addiction, and overdose.

For more information on ABSTRAL and the ABSTRAL REMS program, please visit www.ABSTRAL.com and www.ABSTRALREMS.com or call 1-888-ABSTRAL (1-888-227-8725).

ABSTRAL Clinical Data

A double-blind, placebo-controlled, crossover study evaluated the clinical efficacy of ABSTRAL versus placebo in the treatment of opioid tolerant, adult cancer patients with BTP.

Open-label titration identified a dose of ABSTRAL in which a patient obtained adequate pain relief with tolerable side effects, within the range of 100 mcg to 800 mcg. In the double-blind efficacy study, patients who identified a successful dose were randomized to a sequence of 10 treatments; seven with ABSTRAL and three with placebo.

Of the 131 patients who entered the titration phase of the study, 78 (60 percent) achieved a successful dose during the titration phase. Sixty-six patients entered the double-blind phase and 60 completed the study. The dose of ABSTRAL was determined by titration starting at 100 mcg. The final titrated dose of ABSTRAL for breakthrough cancer pain was not predicted from the daily maintenance dose of opioid used to manage the persistent cancer pain. In a second open-label safety study using an identical titration regimen, 96 of 139 patients (69 percent) who entered the study titrated to a dose in which the patient obtained adequate pain relief with tolerable side effects during the titration phase.

Common adverse reactions associated with ABSTRAL include nausea, constipation, drowsiness and headache.

About ABSTRAL®

ABSTRAL® (fentanyl) sublingual tablets, a rapidly disintegrating sublingual tablet formulation of fentanyl citrate designed for oral transmucosal delivery, is approved in the U.S. for the management of breakthrough pain in cancer patients, 18 years of age
'/>"/>

SOURCE ProStrakan Group plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. MonoSol Rx, LLC Announces Suboxone Sublingual Film Achieves 25% Share of Total U.S. Suboxone Market Volume at Year-End 2010
2. INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray
3. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
4. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
5. Qualitest Receives FDA Approval for Toresmide Tablets (Generic Demadex®) 5 mg, 10 mg, 20 mg, 100 mg, for the Treatment of Edema Associated with Congestive Heart Failure, Renal Disease, or Hepatic Disease
6. Actavis Receives Approval of Valacyclovir Hydrochloride Tablets in the U.S.
7. Florida Pain Clinic Society: 3.7 Billion Oxycodone Tablets Dispensed in U.S.
8. FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents
9. Mylan Launches First Generic Version of Vfend® Tablets
10. Actavis Receives Approval of Pantoprazole Sodium Delayed-Release Tablets, USP in the U.S.
11. Qualitest Pharmaceuticals Issues Voluntary, Nationwide Recall of Hydrocodone Bitartrate and Acetaminophen Tablets, USP 10 mg / 500 mg, NDC 0603-3888-20, 60 Count, Lot Numbers T150G10B, T120J10E and T023M10A and Phenobarbital Tablets, USP 32.4 mg, ND
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... New to Antiretroviral Therapy Respond ... Similarly to Men and ... once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease inhibitor Kaletra(R) ... amount of HIV-1),and improving the immune system (increasing CD4 cells) ...
... a,biopharmaceutical company engaged in the discovery and development ... announced today,that Genentech, a collaborator, has moved a ... into a phase 1 clinical trial,that has begun ... and tolerability of both single and multiple doses ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
(Date:7/10/2014)... 10, 2014 CBPartners, a global leader ... launched a new website. The redesigned site boasts ... access to the firm’s thought pieces, blog posts, and ... platform to showcase our insights, capabilities, and to provide ... Chief Executive Officer, Cyrus Chowdhury. “An enhanced online ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Parker ... protecting the rights of victims injured by defective ... a lawsuit over allegations that the woman’s hidden, ... a power morcellator used during a routine laparoscopic ... against Richard Wolf Medical Instruments Corporation over its ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Nature, not nurture, may ... individual chimpanzees, a new study finds. "As is ... to cognitive [thinking] abilities in chimpanzees," William Hopkins of ... in a news release from the journal Current ... into the evolution of intelligence in humans, Hopkins, team ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... help ease the hot flashes that often accompany menopause, new ... than 50 percent of menopausal women, said Dr. Taraneh Shirazian, ... at the Icahn School of Medicine at Mount Sinai Hospital ... more than 10 hot flashes a day, and she added ...
(Date:7/10/2014)... announcement that the "Mississippi Baby," believed to have been ... have detectable levels of the virus, the Elizabeth Glaser ... but remains hopeful that the scientific breakthrough that allowed ... than two years will continue to help researchers understand ... , "Although we had high hopes that the ...
Breaking Medicine News(10 mins):Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2
... cord by a couple of minutes can have a beneficial effect ... developed countries the tendency of doctors is to cut the umbilical ... problems and allow the mother to hold her baby without delay. ... time ensues before the umbilical cord is severed. ,The ...
... Public Health has been established at Kattankulathur, off Chennai, capital ... will be functioning as part of the SRM Medical College ... SRM University, said the School of Public Health had been ... from the US and the other from the UK. ...
... is a mother’s prayers answered. Five years back Timothy Bingham ... named// it after him- the Bingham syndrome. ,The boy ... like attacks, which rendered him totally paralyzed. It left him in ... of his eyes. ,Yet light has finally broken through ...
... ‘mild, mellow and giggling’ and ‘loved-up with a trippy edge’. ... regular party clubber// in UK’s hot nightspots. , ... by vets. Yet these are now increasingly offered ... , The rocketing use of these drugs have forced UK’s ...
... smoking is well known. But there is one more effect ... you look old, when you are actually// not. It has ... ,Dermatology researchers in the U.S. investigated the effects ... to sunlight. The study observed 82 people who smoked and ...
... paucity of anesthesiologists in the province of Ontario, evident in ... tide over such a situation, Ontario has created two additional ... times for patients. This strategy has proved its weight in ... time tested measure to improve patient care. ...
Cached Medicine News:Health News:New School of Public Health in Chennai 2
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Great for small incisions and excision needs...
Multi-sided, Sharp all around...
...
Medicine Products: